Troy Wilson, Kura Oncology CEO
February 24, 2023 11:01 AM ESTUpdated 02:58 PM
R&D

Ku­ra On­col­o­gy drops mul­ti­ple clin­i­cal pro­grams for J&J-dis­cov­ered tip­i­farnib

Paul Schloesser

Associate Editor

Ku­ra On­col­o­gy is ax­ing all but one clin­i­cal de­vel­op­ment pro­gram in­volv­ing an old Janssen can­di­date.

Ac­cord­ing to an SEC fil­ing on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times